drugset / Trial / NCT01655511

Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers

NCT01655511

Phase 1 Completed 9 enrolled Pfizer
RandomizedCrossoverTriple-blindBasic science

Summary

This study in healthy male and female volunteers will investigate the safety and tolerability of three increasing oral doses of tafamidis

Timeline

Start
2012-07
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafamidis Unknown 240 mg Oral
Subject Tafamidis Unknown 480 mg Oral

Indications

No indication recorded.